201 related articles for article (PubMed ID: 8647968)
1. Combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Lemak NA; Redman JR; Eifel PJ; Tucker SL; Cabanillas FF; Kurzrock R
J Am Acad Dermatol; 1996 Jun; 34(6):1022-9. PubMed ID: 8647968
[TBL] [Abstract][Full Text] [Related]
2. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Winkler CF; Sausville EA; Ihde DC; Fischmann AB; Schechter GP; Kumar PP; Nibhanupdi JR; Minna JD; Makuch RW; Eddy JL
J Clin Oncol; 1986 Jul; 4(7):1094-100. PubMed ID: 3088220
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
4. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
[TBL] [Abstract][Full Text] [Related]
6. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.
Gottlieb SL; Wolfe JT; Fox FE; DeNardo BJ; Macey WH; Bromley PG; Lessin SR; Rook AH
J Am Acad Dermatol; 1996 Dec; 35(6):946-57. PubMed ID: 8959954
[TBL] [Abstract][Full Text] [Related]
7. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides.
Chinn DM; Chow S; Kim YH; Hoppe RT
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):951-8. PubMed ID: 10192339
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
Hoppe RT; Wood GS; Abel EA
Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
[TBL] [Abstract][Full Text] [Related]
9. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome).
Jones GW; Rosenthal D; Wilson LD
Cancer; 1999 May; 85(9):1985-95. PubMed ID: 10223240
[TBL] [Abstract][Full Text] [Related]
10. [Modern therapy of mycosis fungoides].
Roenigk HH
Hautarzt; 1983 Jun; 34(6):266-72. PubMed ID: 6874333
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas.
Bunn PA; Ihde DC; Foon KA
Int J Cancer Suppl; 1987; 1():9-13. PubMed ID: 3305390
[TBL] [Abstract][Full Text] [Related]
12. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
Kim YH; Martinez G; Varghese A; Hoppe RT
Arch Dermatol; 2003 Feb; 139(2):165-73. PubMed ID: 12588222
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
14. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy.
Vonderheid EC; Van Scott EJ; Wallner PE; Johnson WC
Cancer Treat Rep; 1979 Apr; 63(4):681-9. PubMed ID: 109206
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome.
Kuzel TM; Roenigk HH; Samuelson E; Herrmann JJ; Hurria A; Rademaker AW; Rosen ST
J Clin Oncol; 1995 Jan; 13(1):257-63. PubMed ID: 7799028
[TBL] [Abstract][Full Text] [Related]
16. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas.
Bunn PA; Ihde DC; Foon KA
Cancer; 1986 Apr; 57(8 Suppl):1689-95. PubMed ID: 3485012
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
Kim YH; Chow S; Varghese A; Hoppe RT
Arch Dermatol; 1999 Jan; 135(1):26-32. PubMed ID: 9923777
[TBL] [Abstract][Full Text] [Related]
18. Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas.
Bunn PA; Fischmann AB; Schechter GP; Kumar PP; Ihde DC; Cohen MH; Fossieck BE; Gazdar AF; Matthews MJ; Eddy JL; Minna JD
Cancer Treat Rep; 1979 Apr; 63(4):713-7. PubMed ID: 109208
[No Abstract] [Full Text] [Related]
19. Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.
Funk A; Hensley F; Krempien R; Neuhof D; Van Kampen M; Treiber M; Roeder F; Timke C; Herfarth K; Helmbold P; Debus J; Bischof M
Eur J Dermatol; 2008; 18(3):308-12. PubMed ID: 18474461
[TBL] [Abstract][Full Text] [Related]
20. Combined total skin radiotherapy and immune checkpoint inhibitors: A promising potential treatment for mycosis fungoides and Sezary syndrome.
Elsayad K; Stadler R; Steinbrink K; Eich HT
J Dtsch Dermatol Ges; 2020 Mar; 18(3):193-197. PubMed ID: 32077638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
